Flynn James E

Director Flynn James E purchases 5,000,000 shares at $5.00 for $25,000,000, raising holdings to 6.21M shares (+413.9%)

Flynn James E, a Director, executed 4 separate purchases totaling 5,000,000 (5.00M shares) for $25,000,000.00 on 2026-02-27 at a blended average price of $5.00, substantially increasing his position from 1.21M to 6.21M shares. This represents a major commitment of capital ($25.0M) and a dramatic 413.9% increase relative to pre-transaction holdings. His prior buys at Larimar have demonstrated strong performance: all 3 prior trades at LRMR (each executed on 2025-07-31) posted +34.7% returns over 90 days, and his cross-ticker track record shows 5 prior buys averaging +19.5% 90-day returns with a 60% win rate. The current stock price of $5.23 is 52-week low near the $1.71–$5.95 range and up +47.7% over 30 days and +67.6% over 90 days. Notably, a cluster pattern is evident: 3 other insiders also bought within the past 14 days, signaling coordinated accumulation at the board level.

Director Flynn James E sold 742,574 shares ($70.9M) at $95.44 on 2025-11-24; stock now $109.53, up 17.3% in 30 days.

Director Flynn James E executed 2 separate sales totaling 742,574 shares for $70,874,975.44 at $95.44 on 2025-11-24, reducing his holdings by 8.2% to 8,299,225 shares. The stock has appreciated to $109.53 since the sale, representing a +17.3% gain in the 30 days following the transaction—a notably poor 30-day outcome by his own cross-ticker historical standard, where his 15 prior sells averaged a 30-day return of -18.5%. His prior 2 sales at NUVL (both on 2024-10-22) posted 30-day returns of -5.1%, indicating his recent sell activity at this ticker has not preceded weakness. Against the backdrop of Nuvalent's substantial unprofitability (net income $-122,437,000.00 over the most recent full fiscal year) and market cap of $342,761,429.52, this sale of $70.9M represents a significant liquidation by a director but arrives amid strong positive price momentum rather than stock distress.

Director James E Flynn purchases 9.38M shares for $30.0M at $3.20 at unprofitable Larimar Therapeutics (LRMR)

Flynn James E, a Director, executed 3 separate purchases totaling 9,375,000 shares for $30,000,000.00 at $3.20 on 2025-07-31, bringing his post-transaction holdings to 7,321,129 shares. The scale of this acquisition—$30.0M deployed at a single price point on a single day—represents a material capital commitment to the company. LRMR is unprofitable, reporting net income of $-29,281,000.00 and zero revenue in the latest quarter, with a market cap of $211,932,322.52; Flynn's purchase now represents a substantial position in an early-stage or distressed biotech. Against his own same-ticker history, Flynn's prior buy at LRMR on 2024-02-16 showed 90-day performance of -15.0%, and his cross-ticker buy track record shows a 0.00% win rate at the 90-day mark, yet the stock has risen 57.6% over the past 90 days from its lows (currently $3.31, up 3.4% in 30 days). The timing and magnitude of this purchase, combined with the company's negative financials, warrant examination of whether this reflects insider valuation assessment, participation commitment, or other material information asymmetries.

10% owner Flynn James E sold 740,149 shares at $18.46 for $13,663,150.54 on 2025-06-27

Flynn James E, a 10% owner, executed 2 separate sales totaling 740,149 (740.1K shares) for $13,663,150.54 at $18.46 on 2025-06-27, reducing his stake by 13.2% to 4.89M shares. At SPRY specifically, all 5 of his prior trades at this ticker were sells executed on 2024-11-11 and 2024-11-12, and all 5 were well-timed at the 90-day mark, with subsequent declines ranging from -26.3% to -33.9%. His cross-ticker track record shows a 66.67% well-timed rate on 15 prior sells with an average 90-day return of -20.0%. The current stock price of $16.09 is -11.6% from its 52-week high of $18.20, though it is +11.5% over the past 30 days and +23.3% over 90 days. Fundamental context shows the company posted revenue of $7,973,000.00 in the latest quarter with a net loss of $-33,940,000.00, a P/E of 201.12, and a market cap of $1,580,256,196.49. The seller's timing pattern at this specific ticker and his demonstrated track record of well-timed exits warrant close observation of post-transaction stock performance.

10% Owner Flynn James E sold 563,270 shares ($10.1M) in 8 transactions at blended avg $18.01, reducing holdings by 9.7% to 5.26M shares

Flynn James E, a 10% owner, executed 8 separate sales totaling 563,270 shares for $10,143,705.51 on November 11–12, 2024, at prices ranging from $17.16 to $18.15. The blended average price of $18.01 is notably above the current price of $14.08 (down 19.5% from the 52-week high of $17.49 and down 5.8% in the past 30 days). The company's fundamentals are deteriorating: annual revenue growth was -97.7%, the latest quarterly revenue was $2,068,000.00 (down sharply), and net income was $-19,128,000.00, reflecting ongoing losses. The sale reduces his stake from 5,820,598 shares to 5,257,328 shares (5.26M), a 9.7% reduction. His cross-ticker track record shows 7 prior sells with a 0.00% well-timed rate and an average 90-day return of +1.7%, indicating his past sales have not preceded sustained declines. The scale of this liquidation in the context of collapsing revenue and operating losses merits close attention to whether company distress or capital needs are driving the transaction.

Director Flynn James E sold 2,000,000 shares (2.00M) for $195,500,000.00 at NUVL on 2024-10-22

Director Flynn James E sold 2 separate tranches totaling 2,000,000 shares for $195,500,000.00 at a blended average price of $97.75, reducing his holdings from 10,670,512 shares to 8,670,512 shares (-18.7% reduction). The company is unprofitable with net income of -$57,166,000.00 over its most recent full fiscal year, and the current stock price of $93.63 reflects a -16.5% decline from the 52-week high of $112.17. This large-scale divestiture by a director of an unprofitable biotech company, occurring at prices above current levels, merits investor attention given the combination of substantial share reduction and the company's negative earnings backdrop.

Flynn James E (10% Owner) acquires 70,000 shares for $1,260,000.00 in 2 transactions at $18.00; holdings rise to 897,587 shares

10% owner Flynn James E purchased 70,000 shares in two separate $630,000 tranches on 2024-09-17 at $18.00 per share, increasing total holdings by 8.5% to 897,587 shares post-transaction. The purchase occurred at a price $9.07 below the current market price of $27.07 (as of filing date), suggesting the transaction executed during the early trading period following the recent listing (3 trading days old). Note: this filing contains derivative conversion activity whose full details reside in Form 4 Table II and are not yet populated in our database; the reported Table I position should not be interpreted as the insider's complete holdings. The magnitude of the acquisition and the timing relative to the company's recent public emergence merit tracking, though interpretation is constrained by the absence of historical trading patterns at this ticker and the limited public price history available.